Diagnosis of preeclampsia with soluble Fms–like tyrosine kinase 1/placental growth factor ratio: an inter–assay comparison

Andersen, Louise Bjørkholt; Frederiksen-Møller, Britta; Havelund, Kathrine Work; Dechend, Ralf; Jørgensen, Jan Stener; Jensen, Boye L.; Nielsen, Jan; Lykkedegn, Sine; Barington, Torben; Christesen, Henrik Thybo

doi:10.1016/j.jash.2014.11.008

Cited by 37 publications

(25 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These inter-assay differences are less pronounced in values under 225, which encompasses most of the clinical relevant measurements. This confirms the observation of another study that compared the clinical performance of the both assay platforms [20]. Differences between assay results may be due to standardization problems, especially when an international standard preparation is not available.…”

Section: Discussionsupporting

confidence: 87%

“…In general, the performance of the new bioassays from BRAHMS KRYPTOR showed no significant discrepancies as related to sensitivity and specificity in ruling out patients with early onset and ruling out patients with late onset preeclampsia. Another very recent study [20] found higher sensitivity and specificity in diagnosing early onset preeclampsia and higher sensitivity but lower specificity in late onset preeclampsia.…”

Section: Discussionmentioning

confidence: 90%

“…The clinical validation of these assays is due to appropriate studies. Besides one study that already includes a larger cohort of patients suffering from preeclampsia [20], future studies are necessary to determine the assay-specific reference values and cut points.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Analytical evaluation of the novel soluble fms-like tyrosine kinase 1 and placental growth factor assays for the diagnosis of preeclampsia

Helden

Weiskirchen

2015

Clinical Biochemistry

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 90%

See 1 more Smart Citation

Analytical evaluation of the novel soluble fms-like tyrosine kinase 1 and placental growth factor assays for the diagnosis of preeclampsia

Helden

Weiskirchen

2015

Clinical Biochemistry

View full text Add to dashboard Cite

“…181,182 Multiple benchtop readers have been developed to measure serum-based biomarkers of pre-eclampsia, specifically Placental Growth Factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1), and glycosylated fibronectin (GlyFn). 183,184 These biomarkers have all shown promise for diagnosis of pre-eclampsia in the third trimester with area under the receiver operator curves (AUROCs) of 0.94 for PlGF, 0.96 for sFlt-1, 0.98 for sFlt-1/PlGF ratio, and 0.99 for GlyFn. 184 …”

Section: Diagnostics For Maternal Healthmentioning

confidence: 99%

Point-of-care diagnostics to improve maternal and neonatal health in low-resource settings

et al. 2017

View full text Add to dashboard Cite

Each day, approximately 830 women and 7,400 newborns die from complications during pregnancy and childbirth. Improving maternal and neonatal health will require bringing rapid diagnosis and treatment to the point of care in low-resource settings. However, to date there are few diagnostic tools available that can be used at the point of care to detect the leading causes of maternal and neonatal mortality in low-resource settings. Here we review both commercially available diagnostics and technologies that are currently in development to detect the leading causes of maternal and neonatal mortality, highlighting key gaps in development where innovative design could increase access to technology and enable rapid diagnosis at the bedside.

show abstract

“…Circulating biomarkers are increasingly used in risk stratification and therapeutic decision-making of patients with heart failure (HF) [1][2][3]. In many cardiovascular (CV) conditions, complex biological and neurohormonal responses are involved in adaptive or inappropriate CV remodeling [4][5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Sflt-1 in heart failure: relation with disease severity and biomarkers

Gruson

Hermans

Ferracin

et al. 2016

Scandinavian Journal of Clinical and Laboratory Investigation

View full text Add to dashboard Cite

Soluble fms-like tyrosine kinase-1 (sFlt-1) is an endogenous inhibitor of endothelial growth factors, such as placental growth factor (PlGF), which modulates cardiovascular (CV) remodeling. We determine sFlt-1 levels in patients with heart failure (HF) and its relationship to adverse cardiovascular (CV) events and biomarkers of cardiovascular risk. Levels of sFlt-1 and PlGF levels were also determined in healthy volunteers and patients with type 2 diabetes mellitus (T2DM). SFlt-1 and PlGF were clearly increased in HF patients in comparison to T2DM patients or healthy subjects (p < 0.01). Concentration of sFlt-1 was related to HF severity (p < 0.001) and was correlated to NT-proBNP (ρ = 0.37, p < 0.01), soluble ST2 (ρ = 0.52, p < 0.01), Galectin-3 (ρ = 0.38, p < 0.01), aldosterone (ρ = 0.25, p = 0.01) and PTH(1-84) (ρ = 0.38, p < 0.01). Furthermore, sFlt-1 levels were associated to long-term CV risk. These results suggest a potential role of sFlt-1 in HF and its potential role as biomarker of CV risk.

show abstract

Diagnosis of preeclampsia with soluble Fms–like tyrosine kinase 1/placental growth factor ratio: an inter–assay comparison

Cited by 37 publications

References 37 publications

Analytical evaluation of the novel soluble fms-like tyrosine kinase 1 and placental growth factor assays for the diagnosis of preeclampsia

Analytical evaluation of the novel soluble fms-like tyrosine kinase 1 and placental growth factor assays for the diagnosis of preeclampsia

Point-of-care diagnostics to improve maternal and neonatal health in low-resource settings

Sflt-1 in heart failure: relation with disease severity and biomarkers

Contact Info

Product

Resources

About